AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25823991 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g Fibersol-2
Number of subjects: 19
Study 25823991 — intervention group
Group type: COMPARATOR
Intervention: 0 g Fibersol-2 (Control)
Number of subjects: 19
Study 25823991 — intervention group
Group type: COMPARATOR
Intervention: 5 g Fibersol-2
Number of subjects: 19
Study 23716156 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU of vitamin D3 per month (Group A)
Number of subjects: 51
Study 23716156 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU of vitamin D3 per month (Group B)
Number of subjects: 51
Study 23716156 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU of vitamin D3 initially, then adjusted to 50,000 IU per month (Group C)
Number of subjects: 51
Study 21151012 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin A1c (HbA1c) quintiles
Number of subjects: 19858
Study 21151012 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin A1c (HbA1c) clinical cutpoints
Number of subjects: 19858
Study 21151012 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for body mass index (BMI)
Number of subjects: 19858
Study 19796732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Pessary
Number of subjects: 0
Study 19796732 — intervention group
Group type: COMPARATOR
Intervention: Cerclage
Number of subjects: 0
Study 19796732 — intervention group
Group type: COMPARATOR
Intervention: Progesterone
Number of subjects: 0
Study 17585259 — intervention group
Group type: EXPERIMENTAL
Intervention: Release of the talocalcaneal interosseous ligament (TCIL)
Number of subjects: 46
Study 17585259 — intervention group
Group type: COMPARATOR
Intervention: No release of the talocalcaneal interosseous ligament (TCIL)
Number of subjects: 46
Study 15036674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatinum based combination chemotherapy (with adriamycin or methotrexate)
Number of subjects: 620
Study 15036674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no neoadjuvant chemotherapy)
Number of subjects: 620
Study 11437193 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-lesson, 6-month classroom curriculum to reduce television, videotape, and video game use
Number of subjects: 0
Study 11437193 — intervention group
Group type: COMPARATOR
Intervention: Control school (no intervention)
Number of subjects: 0
Study 9612112 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment of factor XIII twice daily for ten days (treatment group, n = 16)
Number of subjects: 24
Study 9612112 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 24
Study 7838916 — intervention group
Group type: EXPERIMENTAL
Intervention: R10 min/3 mg
Number of subjects: 8
Study 7838916 — intervention group
Group type: EXPERIMENTAL
Intervention: R1h/5 mg
Number of subjects: 8
Study 7838916 — intervention group
Group type: EXPERIMENTAL
Intervention: R4h/9 mg
Number of subjects: 8
Study 7838916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8
Study 3377148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.05 mg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 18
Study 3377148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.1 mg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 18
Study 3377148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.2 mg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 18
Study 3377148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.05 mg/kg
Number of subjects: 18
Study 31130558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountain residents
Number of subjects: 1346
Study 31130558 — intervention group
Group type: COMPARATOR
Intervention: Downtown residents
Number of subjects: 1346
Study 29373645 — intervention group
Group type: EXPERIMENTAL
Intervention: External stenting of SVGs (17 SVGs in left territory, 18 SVGs in right territory)
Number of subjects: 35
Study 29373645 — intervention group
Group type: COMPARATOR
Intervention: Non-stented SVGs (20 SVGs in left territory, 18 SVGs in right territory)
Number of subjects: 35
Study 28720079 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led physical activity intervention
Number of subjects: 408
Study 28720079 — intervention group
Group type: COMPARATOR
Intervention: Usual center programming
Number of subjects: 408
Study 26174719 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic arm (200 mg of atazanavir twice daily for patients with unfavourable genotypes)
Number of subjects: 80
Study 26174719 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose arm (400 mg of atazanavir once daily)
Number of subjects: 80
Study 23429637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for physical activity self-monitoring
Number of subjects: 96
Study 23429637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for dietary self-monitoring
Number of subjects: 96
Study 23429637 — intervention group
Group type: COMPARATOR
Intervention: Non-app users for physical activity self-monitoring
Number of subjects: 96
Study 23429637 — intervention group
Group type: COMPARATOR
Intervention: Paper journal users for dietary self-monitoring
Number of subjects: 96
Study 20840347 — intervention group
Group type: EXPERIMENTAL
Intervention: synchronous balneophototherapy (sBPT) consisting of narrowband UVB PT with 311 nm and synchronous bathing in 10% Dead Sea salt solution
Number of subjects: 367
Study 20840347 — intervention group
Group type: COMPARATOR
Intervention: narrowband UVB phototherapy (PT) alone
Number of subjects: 367
Study 19819665 — intervention group
Group type: EXPERIMENTAL
Intervention: SC morphine plus rHuPH20 (150U)
Number of subjects: 13
Study 19819665 — intervention group
Group type: COMPARATOR
Intervention: SC morphine plus placebo (normal saline)
Number of subjects: 13
Study 19819665 — intervention group
Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 13
Study 16723653 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant Group (n = 62)
Number of subjects: 118
Study 16723653 — intervention group
Group type: COMPARATOR
Intervention: Denture Group (n = 56)
Number of subjects: 118
Study 15622663 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 20 mg i.m.
Number of subjects: 353
Study 15622663 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg i.m.
Number of subjects: 353
Study 11689738 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20 g x d(‐1) for 5 days, then 5 g x d(‐1) for 5 days)
Number of subjects: 19
Study 11689738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch, same dosage regimen as Cr group)
Number of subjects: 19
Study 9142590 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 17
Study 9142590 — intervention group
Group type: COMPARATOR
Intervention: Conventional Unsynchronized Intermittent Mandatory Ventilation (IMV)
Number of subjects: 17
Study 8196995 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation (HFJV)
Number of subjects: 9
Study 8196995 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 9
Study 2574108 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 240
Study 2574108 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 240
Study 1103750 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol
Number of subjects: 10
Study 1103750 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosols
Number of subjects: 10
Study 1103750 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 31783127 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory span intervention for 20 sessions over 4 weeks
Number of subjects: 80
Study 31783127 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 31218889 — intervention group
Group type: EXPERIMENTAL
Intervention: Run Zao Zhi Yang capsule (RZZYC)
Number of subjects: 240
Study 31218889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 31218889 — intervention group
Group type: COMPARATOR
Intervention: Run Zao Zhi Yang capsule (RZZYC) and Placebo
Number of subjects: 240
Study 29192639 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg ropivacaine 1%
Number of subjects: 60
Study 29192639 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ropivacaine 1%
Number of subjects: 60
Study 29192639 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ropivacaine 1%
Number of subjects: 60
Study 26562074 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMF treatment (MAGCELL ARTHRO device), delivered a sinusoidal magnetic field of 4-12 Hz, magnetic flux density of 105 mT, treatment twice a day for 5 min over 18 days.
Number of subjects: 57
Study 26562074 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (placebo device)
Number of subjects: 57
Study 26562074 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMF treatment
Number of subjects: 57
Study 26562074 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 57
Study 23415013 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel alone (double therapy)
Number of subjects: 573
Study 23415013 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (triple therapy)
Number of subjects: 573
Study 21531587 — intervention group
Group type: COMPARATOR
Intervention: Foam sclerotherapy with compression stockings (CG)
Number of subjects: 40
Study 21531587 — intervention group
Group type: COMPARATOR
Intervention: Foam sclerotherapy without compression stockings (WCG)
Number of subjects: 40
Study 19881375 — intervention group
Group type: EXPERIMENTAL
Intervention: Excisions performed along the visible outer margins of erythema or induration area surrounding the tumor
Number of subjects: 0
Study 19881375 — intervention group
Group type: COMPARATOR
Intervention: Traditional wide excision with wide skin margins
Number of subjects: 0
Study 17190414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular autorotation test (VAT)
Number of subjects: 73
Study 17190414 — intervention group
Group type: COMPARATOR
Intervention: Videonystagmography (VNG) test
Number of subjects: 73
Study 17190414 — intervention group
Group type: COMPARATOR
Intervention: Caloric test
Number of subjects: 73
Study 14708047 — intervention group
Group type: COMPARATOR
Intervention: Early-onset group (under age 40)
Number of subjects: 70
Study 14708047 — intervention group
Group type: COMPARATOR
Intervention: Expression of p53 in early-onset group
Number of subjects: 70
Study 14708047 — intervention group
Group type: COMPARATOR
Intervention: Late-onset group (over age 40)
Number of subjects: 70
Study 10793598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (group A, n = 28)
Number of subjects: 53
Study 10793598 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure (group B, n = 25)
Number of subjects: 53
Study 9238392 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin pairs (monozygotic)
Number of subjects: 62
Study 9238392 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin pairs (dizygotic)
Number of subjects: 62
Study 9238392 — intervention group
Group type: EXPERIMENTAL
Intervention: Monozygotic twin pairs
Number of subjects: 62
Study 1731135 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive ethics education intervention (EI)
Number of subjects: 88
Study 1731135 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited intervention
Number of subjects: 88
Study 1731135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 1731135 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AIDS
Number of subjects: 88
Study 1731135 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with other diagnoses
Number of subjects: 88
Study 1731135 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with malignancy
Number of subjects: 88
Study 6393945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat, high unrefined carbohydrate (HC) diet
Number of subjects: 5
Study 6393945 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate (LC) diet
Number of subjects: 5
Study 30879003 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1981 40 mg TID
Number of subjects: 28
Study 30879003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29299989 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 1000mg with 10mg of piperine daily
Number of subjects: 118
Study 29299989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 27195662 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BRS)
Number of subjects: 0
Study 27195662 — intervention group
Group type: COMPARATOR
Intervention: Best contemporary metallic drug-eluting stents (DES)
Number of subjects: 0
Study 24843205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dembone® (freeze-dried bone allograft)
Number of subjects: 30
Study 24843205 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bone® (modified hydroxyapatite)
Number of subjects: 30
Study 23529988 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diet (baked products enriched with β‐glucans, folic acid, long‐chain and short‐chain n‐3 fatty acids, tocopherols)
Number of subjects: 16
Study 23529988 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diet
Number of subjects: 16
Study 19321117 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% lyocell clothing and bedding
Number of subjects: 30
Study 19321117 — intervention group
Group type: COMPARATOR
Intervention: 100% cotton clothing and bedding
Number of subjects: 30
Study 17965442 — intervention group
Group type: EXPERIMENTAL
Intervention: C5aR-antagonist AcF-(OpdChaWR) (PMX53)
Number of subjects: 21
Study 17965442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15200658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (PB)
Number of subjects: 100
Study 15200658 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate (CH)
Number of subjects: 100
Study 11753768 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific back muscle exercises
Number of subjects: 12
Study 11753768 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific fitness training
Number of subjects: 12
Study 11753768 — intervention group
Group type: COMPARATOR
Intervention: Passive treatment or no treatment
Number of subjects: 12
Study 11753768 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of specific back muscle exercises and non-specific fitness training
Number of subjects: 12
Study 9586884 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose cranial irradiation (SRT) of 36 Gy
Number of subjects: 22
Study 9586884 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose cranial irradiation (RRT) of 23.4 Gy
Number of subjects: 22
Study 9586884 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (Y/SRT)
Number of subjects: 22
Study 9586884 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (O/RRT)
Number of subjects: 22
Study 9586884 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (Y/RRT)
Number of subjects: 22
Study 9586884 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (O/SRT)
Number of subjects: 22
Study 7988168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day suicide intervention training program
Number of subjects: 36
Study 2645441 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein patch closure (n = 62)
Number of subjects: 136
Study 2645441 — intervention group
Group type: COMPARATOR
Intervention: Primary closure (n = 60)
Number of subjects: 136
Study 31174214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake
Number of subjects: 345
Study 28892496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 1609
Study 28892496 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend (CSB)
Number of subjects: 1609
Study 28892496 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS with soy isolate (SI)
Number of subjects: 1609
Study 28892496 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS with dehulled soy (DS)
Number of subjects: 1609
Study 28892496 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isolate (SI)
Number of subjects: 1609
Study 28892496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehulled soy (DS)
Number of subjects: 1609
Study 28892496 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% milk protein
Number of subjects: 1609
Study 28892496 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% milk protein
Number of subjects: 1609
Study 25809413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone at 0.75 mg/kg/day
Number of subjects: 66
Study 25809413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 23496265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of losartan 50 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 0
Study 23496265 — intervention group
Group type: COMPARATOR
Intervention: Maximum dose of losartan (100 mg)
Number of subjects: 0
Study 20833549 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery TKA (MIS group)
Number of subjects: 30
Study 20833549 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA (conventional group)
Number of subjects: 30
Study 20833549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MIS and conventional)
Number of subjects: 30
Study 19457937 — intervention group
Group type: EXPERIMENTAL
Intervention: ITP regimen (ifosfamide 1.5 g/m² daily on days 1-3, cisplatin 70 mg/m² on day 2, paclitaxel 175 mg/m² on day 1)
Number of subjects: 153
Study 19457937 — intervention group
Group type: COMPARATOR
Intervention: IP regimen (ifosfamide 1.5 g/m² daily on days 1-3, cisplatin 70 mg/m² on day 2)
Number of subjects: 153
Study 19457937 — intervention group
Group type: EXPERIMENTAL
Intervention: ITP regimen
Number of subjects: 153
Study 19457937 — intervention group
Group type: COMPARATOR
Intervention: IP regimen
Number of subjects: 153
Study 16393594 — intervention group
Group type: EXPERIMENTAL
Intervention: Single one‐pass pulsed dye laser treatment (595 nm, 7 J/cm2 fluence, 7 mm spot size, 1.5‐millisecond pulse duration, 30‐millisecond spray, 20‐millisecond delay of dynamic cooling) at the time of suture removal (2 weeks after excision)
Number of subjects: 20
Study 16393594 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment with laser)
Number of subjects: 20
Study 14680672 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims-based feedback about patterns of HbA1C measurement, educational materials, and practice aids
Number of subjects: 0
Study 14680672 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study 10728742 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 480
Study 10728742 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 480
Study 10728742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 9175692 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy with bilateral salpingo‐oophorectomy (N=91)
Number of subjects: 164
Study 9175692 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy (abdominal or vaginal) only or hysterectomy with unilateral salpingo‐oophorectomy (N=73)
Number of subjects: 164
Study 1413555 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoluminant stimuli
Number of subjects: 0
Study 1413555 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalent luminance contrast stimuli
Number of subjects: 0
Study 1413555 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmasked stimuli
Number of subjects: 0
Study 1413555 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli embedded in luminance noise
Number of subjects: 0
Study 3158674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg bid
Number of subjects: 18
Study 3158674 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg bid
Number of subjects: 18
Study 29333721 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g·h‐1 (LG)
Number of subjects: 10
Study 29333721 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g·h‐1 (HG)
Number of subjects: 10
Study 29333721 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g·h‐1 (LGF)
Number of subjects: 10
Study 29333721 — intervention group
Group type: EXPERIMENTAL
Intervention: 112.5 g·h‐1 (HGF)
Number of subjects: 10
Study 29333721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29333721 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g·h‐1 glucose-fructose ingestion
Number of subjects: 10
Study 27388860 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 0
Study 27388860 — intervention group
Group type: COMPARATOR
Intervention: Online self-study module
Number of subjects: 0
Study 25372911 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior transseptal approach (n=47)
Number of subjects: 91
Study 25372911 — intervention group
Group type: COMPARATOR
Intervention: Conventional left atriotomy (n=44)
Number of subjects: 91
Study 24092691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g/kg)
Number of subjects: 10
Study 24092691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20052587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribosomal prophylaxis
Number of subjects: 60
Study 17574461 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (mean maintenance dosage 7.7 mg/kg/day, range: 4-16 mg/kg/day)
Number of subjects: 24
Study 17574461 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 24
Study 16364497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic visual noise (visuo-spatial interference)
Number of subjects: 42
Study 16364497 — intervention group
Group type: COMPARATOR
Intervention: Control condition (blank computer screen)
Number of subjects: 42
Study 12502672 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg daily
Number of subjects: 23
Study 12502672 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg daily
Number of subjects: 23
Study 12502672 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg daily
Number of subjects: 23